AN2 Therapeutics, Inc. (ANTX): Cash & Equivalents
$19.94M
As of 2025-12-31
$44.32M
As of 2026-06-30
-9.9%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.94M | -6.6% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $21.35M | +36.5% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $15.65M | -42.5% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $27.22M | +125.0% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $12.10M | n/a | 2023-03-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $19.94M | -6.6% |
| Lifevantage Corp (LFVN) | 2025-06-30 | $20.20M | +19.6% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $59.05M | -46.7% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $48.30M | -38.1% |
| Rallybio Corp (RLYB) | 2025-12-31 | $31.37M | +125.7% |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $15.65M | +417.3% |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $55.16M | +696.8% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $90.0K | -86.7% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $57.98M | -30.6% |
Compare ANTX, LFVN, OKUR, QTTB side by side · Screen every company in Pharmaceutical Preparations ↗